SCHEMBL18932151

SCHEMBL18932151

NC(=O)c1cccc2cn(-c3ccc(C4CCCCC4)cc3)nc12

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 20/20 0.80
PARP2 Q9UGN5 13/20 0.78
PARP3 Q9Y6F1 13/20 0.78
TNKS O95271 1/20 0.78
CHRM2 P08172 1/20 0.78
CHRM1 P11229 1/20 0.78
SLC6A2 P23975 1/20 0.78
SLC6A4 P31645 1/20 0.78
ADRA1A P35348 1/20 0.78
SLC6A3 Q01959 1/20 0.78
KCNH2 Q12809 1/20 0.78
DYRK1A Q13627 1/20 0.78
PARP15 Q460N3 1/20 0.78
PARP14 Q460N5 1/20 0.78
PARP10 Q53GL7 1/20 0.78
PARP12 Q9H0J9 1/20 0.78
TNKS2 Q9H2K2 1/20 0.78
PARP4 Q9UKK3 1/20 0.78
DYRK1B Q9Y463 1/20 0.78
HRH3 Q9Y5N1 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28612193 0.89 PARP1 (1.00) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL1422151 0.88 PARP1 (1.00) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL1421952 0.88 PARP1 (1.00) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL1421875 0.88 PARP1 (1.00) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL567840 0.87 PARP1 (0.98) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL567839 0.87 PARP1 (0.98) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL1422061 0.87 PARP1 (0.98) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL28370623 0.87 PARP1 (0.98) PARP1PARP2PARP3TNKSCHRM2
SCHEMBL24301101 0.86 PARP1 (0.69) PARP1PARP2PARP3TNKSCHRM2
SCHEMBL21036416 0.86 PARP1 (0.69) PARP1PARP2PARP3TNKSCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170342498-A1 PARP GENOMIC VARIANTS CONFERRING RESISTANCE AND SENSITIZATION TO CHEMOTHERAPY UNDER INHIBITION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2017-11-30 US disclosed
US-20170157212-A1 CDK MODULATORS AND METHODS FOR THE TREATMENT OF CANCER SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-06-08 US disclosed
US-20170137403-A1 REGIOSELECTIVE N-2 ARYLATION OF INDAZOLES MERCK SHARP & DOHME CORP. (US) 2017-05-18 US disclosed
US-9580407-B2 Regioselective N-2 arylation of indazoles MERCK SHARP & DOHME CORP. (US) 2017-02-28 US disclosed
US-20150299167-A1 Regioselective N-2 Arylation of Indazoles MERCK SHARP & DOHME CORP. (US) 2015-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342498-A1 PARP GENOMIC VARIANTS CONFERRING RESISTANCE AND SENSITIZATION TO CHEMOTHERAPY UNDER INHIBITION PARP8, PARP1, PARP11 PARP1 2/4885PARP2 4/4885PARP3 6/4885
US-20150299167-A1 Regioselective N-2 Arylation of Indazoles PARP2, PARP1, PARP12 PARP1 2/4885PARP2 1/4885PARP3 5/4885
US-20170137403-A1 REGIOSELECTIVE N-2 ARYLATION OF INDAZOLES PARP2, PARP1, PARP12 PARP1 2/4885PARP2 1/4885PARP3 5/4885
US-20170157212-A1 CDK MODULATORS AND METHODS FOR THE TREATMENT OF CANCER CDK12, CDK1, CDKL2 PARP1 571/4885PARP2 292/4885PARP3 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.